Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

0913693 B.C. Ltd (TSV:RP)

0.0150 UNCHANGED
Last Price Updated: 3:58 PM EST, Feb 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 0913693 B.C. Ltd

< Previous 1 2 Next >
News headline image
Canoe Financial Bets Big on Roper (NASDAQ: RP), Adds $123 Million Worth of Shares: Should Investors Follow? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
RealPage Announces Strategic Partnership with Habitat for Humanity International to Build Housing in Local Communities
From RealPage, Inc.
Via Business Wire
News headline image
RealPage Accelerates the Pace of Innovation for Multifamily with Market-Leading AI-Enabled Front Office Suite
From RealPage, Inc.
Via Business Wire
News headline image
RepliCel Provides Corporate Update
Via ACCESSWIRE
News headline image
RepliCel Announces Material Patent Milestones in Key Markets
Via ACCESSWIRE
News headline image
RealPage Unveils New Multifamily Rental Trends
From RealPage
Via Business Wire
News headline image
RealPage Awarded 2023 ENERGY STAR Partner of the Year for Sustained Excellence
From RealPage
Via Business Wire
News headline image
Key Cannabis Exec Changes You Need To Know About: Curaleaf Names Director Of Social Equity & More Industry Appointments ↗
Curaleaf Names Director Of Social Equity 
Via Benzinga
News headline image
Grabbing Opportunity In Texas Migration Numbers, Rental Fund Buys Dallas-Area Single-Family Home Development ↗
A joint venture between two Fundrise-sponsored funds has led to the acquisition of 18 rental homes in the Ridgeview Villas community in Allen, Texas, north of Dallas.  
Via Benzinga
News headline image
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
Via ACCESSWIRE
News headline image
RepliCel’s Manufacturing Inspected by Japan’s PMDA
After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RepliCel’s Manufacturing Inspected by Japan’s PMDA
Via ACCESSWIRE
News headline image
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
Via ACCESSWIRE
News headline image
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
Via ACCESSWIRE
News headline image
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RepliCel Announces Material Patent Milestones
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc.... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
News headline image
RepliCel Closed Final Tranche of Strategic Investment Commitment
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RepliCel Terminates License Agreement with Shiseido
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RealPage Agrees to Acquire HomeWiseDocs, The Premier Provider of Disclosure Management Services to the Community Association Industry
From RealPage, Inc.
Via Business Wire
News headline image
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc.... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RepliCel Announces Dermal Injector Update
Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE /... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration... 
From RepliCel Life Sciences, Inc.
Via AccessWire
News headline image
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC /... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Economy
News headline image
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
- Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
News headline image
RealPage To Acquire G5, Leader in Real Estate Marketing Optimization
From RealPage, Inc.
Via Business Wire
News headline image
RealPage Announces New Prepaid Debit Card Solution
From RealPage, Inc.
Via Business Wire
News headline image
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 /... 
From RepliCel Life Sciences, Inc.
Via AccessWire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.